Healthcare experts urge India to rewrite clinical trial rules to boost global market share
HYDERABAD Feb 27 (Reuters) - India should take a page from the playbook of countries such as China and Australia if it wants a larger share of the global clinical trials market, healthcare experts said at an industry conference.
As of 2022, India held an 8% share in global clinical trials - which evaluate the safety and effectiveness of new treatments - compared to China's 29%, the U.S.'s 25%, and 38% for the rest of the world, data from consultancy PwC showed.
"There's a lot to learn from what other countries have done to make them clinical trial destinations," BCG India partner Smruthi Suryaprakash said, pointing out that China saw an increase in innovation after easing regulations, while Australia has benefited from offering significant tax incentives.
India's clinical trials research market is rapidly expanding, supported by a diverse patient base, cost-effective solutions, and a growing hospital network, according to U.S.-based GrandView Research, which forecasts revenues exceeding $2 billion by 2030.
"India will be able to capture the clinical trial (market) if we can really work on the speed. I think speed is what is really important to sponsors, either with regulator or being able to recruit patients faster," Suryaprakash added.
Suryaprakash, along with other experts, was speaking as part of a panel at the BioAsia conference in the southern Indian state of Telangana.
Rajeev Raghuvanshi, who heads India's drug regulator, said it was working to make the regulatory process more streamlined for global trials in India, based on feedback from stakeholders.
"We have aligned things every year on average for the last three years," the drugs controller general of India said.
The agency which revamped its trial rules in 2019, had approved about 160 trials in the last three years, he added.
RECRUITING THE RIGHT PATIENTS
Allowing sponsors to raise awareness among patients, such as through advertisements of ongoing studies, would also help India advance as a recruitment site, the experts said.
Advertising studies for experimental treatments could be helpful, especially for patients with rare diseases without many treatment options. It is a common practice in countries such as the U.S. and the U.K.
"You're not able to recruit into the trial because they (patients) do not know that it exists," said Padmaja Lokireddy, an oncologist at Apollo Hospitals (APLH.NS), opens new tab.
That needs to change, experts said.
Some other experts highlighted challenges related to preparing a clinical trial site, ensuring it meets global safety standards and recruiting the right patients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
20 hours ago
- South Wales Argus
UK safari park announces the birth of three lion cubs
The cubs arrived in April to 12-year-old Amber, and have just had their first health checks, confirming two males and a female. West Midlands Safari Park's veterinary team and keepers have named them Nero, Nox, and Nancy. The next steps for the cubs will be an introduction to the outside world, with the keepers allowing them access to an outdoor area, next to the lion house. Just like a domestic cat, the lion cubs will need their second lot of injections and another health check before they are allowed to venture into the great outdoors to meet guests. The birth of the cubs is significant as lions are classed as 'vulnerable' in the wild by the International Union for the Conservation of Nature. The lion cubs' arrival follows a recent baby boom at the park, including three Sumatran tiger cubs, an Indian rhino calf, two blesbok calves, and a barasingha fawn.
Reuters
a day ago
- Reuters
US health chief says Sen. Cassidy promised pick on vaccine panel
WASHINGTON, June 12 (Reuters) - U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said he told U.S. Senator Bill Cassidy that he would allow Cassidy to pick a candidate for a key panel of vaccine advisers. Cassidy, a Republican, serves as chairman the U.S. Senate Health, Education, Labor, and Pensions Committee. "What I told Senator Cassidy is that I would allow him to put one of his candidates on, which we're going to do," Kennedy said on Thursday during an interview on Fox News' "The Story with Martha MacCallum," referring to the vaccine advisory panel. Kennedy on Wednesday named eight members to serve on the U.S. Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices, which advises the agency on who should get the shots after they are approved by the U.S. Food and Drug Administration, after gutting the panel last week.
Reuters
a day ago
- Reuters
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
June 12 (Reuters) - One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's (MRK.N), opens new tab Gardasil vaccine, court records show. Martin Kulldorff, a biostatistician and epidemiologist who publicly criticized COVID-era lockdowns, is one of eight new members named by Kennedy on Wednesday to the Advisory Committee on Immunization Practices, a highly influential panel that recommends which shots should be administered to the American public. Kennedy fired the entire previous 17-member committee of expert vaccine advisers this week, claiming they were "plagued with persistent conflicts of interest" from financial ties to drugmakers. Kulldorff recently served as an expert witness for plaintiffs who accused Merck of concealing the risks of Gardasil, which is intended to prevent cancers caused by human papillomavirus (HPV). In March, a federal judge in North Carolina ruled in favor of Merck in one of those cases that included about 200 lawsuits. At a deposition in October, Kulldorff testified that the plaintiffs paid him $400 an hour and he had already billed for about $33,000 in legal work on the case through late September. He said he also received a $4,000 retainer in the North Carolina case, according to court documents. Kulldorff is also listed as an expert witness in a similar case pending against Merck in Los Angeles state court, records show. Under ACIP's rules, committee members cannot serve as a "paid litigation consultant or expert witness in litigation involving a vaccine manufacturer' during their tenure on the panel. Prior work as an expert witness against drugmakers may require a waiver from the U.S. Centers for Disease Control and Prevention and recusal from votes involving Merck and HPV vaccines. The agency has said in its rules it "will generally consider issuance of waivers in specific situations." Kulldorff did not immediately respond to a request for comment. Merck declined to comment. A spokesman for Kennedy's Health and Human Services Department said on Wednesday that "all newly appointed ACIP members were thoroughly vetted." HHS did not immediately respond to a request for comment on Kulldorff.
